New FDA guidance means that digital therapeutics could get to at-risk patients faster amid the Covid-19 pandemic, and healthcare stakeholders are already reacting.
Digital therapeutics — software-based disease prevention, management, and treatment solutions — has been gaining more interest in recent years.
As an emerging area of digital health, it holds potential for new avenues in patient care — the market is expected to reach nearly $9B by 2025. However, its role remains uncertain as industry adoption is up in the air.
In April, the FDA released a guidance document that waived some of its regulatory requirements for digital health devices — including digital therapeutics — supporting psychiatric disorders (like major depressive disorder, schizophrenia, or substance use disorder). This may help demonstrate how digital therapeutics could be integrated into the current care model.
Want the full post? Become a CB Insights customer.
If you’re already a customer, log in here.